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Abstract
Sputum colour is regarded as a good marker of bacterial involvement in acute exacerbations of chronic obstructive pulmonary disease
(COPD) and guides many physicians in deciding on antibiotic treatment. Although most doctors rely on the sputum colour that is
reported by patients, it can also be assessed using a validated colour chart. In this study, reported sputum colour and assessed sputum
colour were compared as markers of the presence of bacteria, bacterial load, and systemic inﬂammation. Data on 257 exacerbations in
216 patients hospitalized with an acute exacerbation were analysed (mean age, 72 years; mean forced expiratory volume in 1 s,
44.8% ± 17.8% (± standard deviation)). Sputum colour was reported by the patients and assessed at the laboratory with a colour chart.
Subsequently, quantitative sputum cultures were performed. C-reactive protein was measured as a marker of systemic inﬂammation.
A sputum sample was obtained in 216 exacerbations (84%), of which 177 (82%) were representative. A pathogen was identiﬁed in 155
patients (60%). Assessed sputum colour was a better marker of the presence of bacteria (OR 9.8; 95% CI 4.7–20.4; p <0.001) than
reported sputum colour (OR 1.7; 95% CI 1.0–3.0; p 0.041). The sensitivity and speciﬁcity were 73% and 39% for reported sputum col-
our, and 90% and 52% for assessed sputum colour. Assessed sputum colour was clearly related to sputum bacterial load and C-reactive
protein levels, whereas reported sputum colour was not. It is concluded that sputum colour reported by patients is an unreliable
marker of the presence of bacteria in acute exacerbations of COPD. Assessed sputum colour is clearly superior and is also related to
bacterial load and systemic inﬂammation.
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Introduction
Chronic obstructive pulmonary disease (COPD) constitutes
a major health problem. Acute exacerbations of COPD
(AECOPDs) have considerable impact on morbidity, mortal-
ity, and quality of life [1,2]. The hallmark of acute exacerba-
tions is an increase in airway inﬂammation, which can by
triggered by a viral or bacterial infection or changes in envi-
ronmental conditions such as air pollution. This increased
inﬂammation causes frequently reported symptoms such as
increased sputum volume and changes in sputum colour.
While studying the efﬁcacy of antibiotics in acute exacer-
bations, Anthonisen et al. [3] attempted to classify exacerba-
tions according to severity. A type 1 AECOPD is deﬁned by
the triad of increased dyspnoea, sputum volume, and sputum
purulence. In a type 2 AECOPD, two of these symptoms are
present. Type 3 AECOPD is characterized by one of these
three symptoms in addition to one of the following: upper
respiratory infection within the past 5 days; fever without a
cause; increased wheezing; increased cough; or a 20%
increase in respiratory or heart rate as compared with base-
line. Antibiotics were particularly effective in type 1 exacer-
bations [3]. Since this study, sputum colour has been used as
a marker for bacterial infection, and guides many physicians
in deciding whether to prescribe antibiotics. Unfortunately,
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no microbiological analysis was performed in their trial [3].
Whereas Antonisen et al. [3] used change of sputum colour,
other investigators assessed the colour of sputum with a
colour chart on the day of consultation [4,5]. Although these
studies show that a sputum colour chart can be a valuable
tool with which to predict bacterial involvement, most physi-
cians make therapeutic decisions according to the sputum
colour that is reported by patients.
The aim of this study was two-fold: ﬁrst, to compare spu-
tum colour reported by patients with sputum colour
assessed with a colour chart as markers of bacterial pres-
ence in AECOPD; and second, to investigate whether
reported and assessed sputum colour are related to bacterial
load and systemic inﬂammation (C-reactive protein (CRP)).
Materials and Methods
Population
Data from 257 exacerbations from 216 patients admitted for
AECOPD at the Medical Centre Alkmaar, The Netherlands
who were enrolled in a randomized trial from August 2002
to September 2007 were analysed. The goal of that placebo-
controlled trial was to assess the efﬁcacy of doxycycline in
patients hospitalized with AECOPD. Patients aged 45 years
or older with COPD, stage I–IV according to the GOLD
classiﬁcation [6], presenting with an acute (£14 days in dura-
tion) exacerbation of Anthonisen type 1 (increased dyspnoea,
sputum volume, and sputum purulence) [3] or type 2 (two
of three symptoms), and requiring hospitalization were
screened. Exclusion criteria included inability to take oral
medication, fever (‡38.5C), antibiotic treatment for ‡24 h,
steroid treatment (>30 mg of prednisolone equivalent for
more than 4 days), new abnormalities upon chest radiograph,
history of severe AECOPD requiring mechanical ventilation,
recently diagnosed or unresolved lung malignancy, other
infectious diseases requiring antibiotic therapy (e.g. sinusitis),
congestive heart failure (NYHA III–IV), apparent immunodeﬁ-
ciency (e.g. AIDS or immunosuppressive drugs), and impaired
renal function (creatinine clearance, <20 mL/min). Criteria
for hospital admission were adapted from the GOLD work-
shop summary 2001 [6]. All patients provided written
informed consent, and the study was approved by the local
medical ethics committee.
Data collection
Upon admission, sputum colour was recorded as reported
by the patient (referred to as ‘reported sputum colour’ here-
after). White or grey reported colour was interpreted as
mucoid sputum, whereas yellow or green reported colour
was interpreted as purulent. A freshly expectorated sputum
sample and a serum sample were acquired on the ﬁrst day
of admission. Patients were instructed to rinse their mouth
with water before expectorating. The sputum sample was
stored in a refrigerator (4C) before transport to the labora-
tory. Further specimen collection and handling was in accor-
dance with the guidelines of the American Society for
Microbiology [7]. At the laboratory for microbiology, sputum
colour was assessed with a previously validated ﬁve-point
sputum colour chart (BronkoTest; Heredilab Inc., Salt Lake
City, UT, USA) by one of two speciﬁcally instructed analysts.
Colours 1 and 2 are regarded as non-infective and
colours 3–5 as infective (referred to as ‘assessed sputum
colour’ hereafter). Gram stain was performed, and sputum
quality was assessed according to the Bartlett criteria [8]. A
sputum sample with >25 polymorphonuclear leukocytes and
<10 squamous epithelial cells per low-power ﬁeld was
deﬁned as a sputum sample representative of the lower
airways. Subsequently, quantitative cultures were performed.
Bacterial infection was deﬁned as the presence of a potential
pathogen in a representative sputum sample. Serum CRP
(Beckman Coulter Inc., Fullerton, CA, USA) was measured
as a marker of systemic inﬂammation.
Statistical analysis
Data are presented as mean ± standard deviation unless sta-
ted otherwise. Differences among groups were determined
using the chi-Square test or Fisher exact test for nominal
variables, Student’s t-test for normally distributed interval
variables, and the Mann–Whitney U-test for non-normally
distributed variables. Bayesian analysis was performed, with
the calculation of sensitivity, speciﬁcity, positive predictive
value and negative predictive value.
Results
Patients
In the original randomized trial, 265 patients with an exacerba-
tion were enrolled. Eight patients with exacerbation were not
included in the current analysis: two were enrolled at another
centre, two had asthma rather than COPD, two did not meet
the lung function criteria for the diagnosis of COPD, one had a
myocardial infarction, and one had community-acquired pneu-
monia. We evaluated 257 exacerbations in 216 patients
(Table 1). The mean stable state forced expiratory volume in
1 s was 44.8% ± 17.8% of the predicted value.
Sputum purulence was reported in 175 exacerbations
(68%), and mucoid sputum was reported in 82 exacerbations
(32%). The mean duration of the exacerbation prior to
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admission was 5.8 ± 3.7 days. Eighty-one per cent of patients
were treated with maintenance inhaled corticosteroids, and
29% had been treated with systemic corticosteroids for the
current exacerbation. The mean serum CRP level was
55.5 ± 68.1 mg/L.
Sputum samples
A sputum sample was obtained in 216 of 257 exacerbations
(84%), and 177 (82%) of these were found to be representa-
tive of the lower airways (Table 2). According to the sputum
colour charts, 168 sputum samples (78%) were purulent
(Table 2). Agreement between reported and assessed spu-
tum colour was observed in 148 (69%) of 215 exacerbations.
One or more potential pathogens were identiﬁed in 155
exacerbations (60%). Haemophilus inﬂuenzae was the pre-
dominant primary pathogen (52%), followed by Streptococcus
pneumoniae (19%) and Moraxella catarrhalis (19%).
Markers of bacterial infection
Bacteria were found in 51% of patients with reported
mucoid sputum and in 65% of patients with reported puru-
lent sputum (OR 1.7, 95% CI 1.0–3.0, p 0.041) (Table 3).
There was a greater difference in bacterial isolation rates
between assessed sputum colours, as bacterial cultures were
positive in 32% of mucoid and 82% of purulent sputum sam-
ples (OR 9.8, 95% CI 4.7–20.4, p <0.001). The sensitivity and
speciﬁcity for reported sputum colour were 73% and 39%,
respectively. The sensitivity and speciﬁcity for assessed spu-
tum colour were 90% and 52%, respectively.
Bacterial load
The mean bacterial load of the isolated primary pathogens
was 7.6 ± 1.4 CFU/mL. A signiﬁcant difference in log bacte-
rial load was observed between purulent and mucoid sputum
as assessed by a sputum colour chart (7.6 ± 1.4 CFU/mL vs.
6.7 ± 1.2 CFU/mL, p 0.009), but not between purulent and
mucoid sputum as reported by patients (7.6 ± 1.4 CFU/mL
vs. 7.4 ± 1.2 CFU/mL, p 0.30) (Fig. 1).
CRP
The median serum CRP level was 26 mg/L (interquartile
range (IQR) 7–79). We found no signiﬁcant difference in
TABLE 1. Baseline characteristics of 257 cases of exacerba-





Age (years) 72.0 ± 9.3
FEV1 (% predicted) 44.8 ± 17.8
GOLD stage, n (%)a
I (FEV1 ‡ 80% of predicted) 9 (4)
II (FEV1 ‡50% of predicted and <80% of predicted) 83 (32)
III (FEV1 ‡30% of predicted and <50% of predicted) 100 (39)
IV (FEV1 <30% of predicted) 65 (25)
Smoker, n (%) 232 (90)
Recent smokerc, n (%) 75 (29)
Pack years 39.9 ± 24.1
Sputum colour reported by patients, n (%)
Mucoid 82 (32)
Purulent 175 (68)
Duration of AECOPD (days) 5.8 ± 3.7
PaO2 (mmHg) 68.6 ± 13.5
PaCO2 (mmHg) 42.7 ± 9.4
ICS treatment prior to admission, n (%) 209 (81)
SCS treatment prior to admission, n (%)b 74 (29)
Serum CRP (mg/L) 55.5 ± 68.1
Values are listed as mean ± SD unless stated otherwise.
FEV1, forced expiratory volume in 1 s; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; AECOPD, acute exacerbation of chronic obstructive
pulmonary disease; ICS, inhaled corticosteroid; SCS, systemic corticosteroid;
CRP, C-reactive protein.
aBased on the last recorded value in a stable state.
bOral steroid treatment for 2 weeks preceding admission.
cA person who smokes daily or occasionally in the last six months.
TABLE 2. Sputum colour and cultures, n = 216
n (%)

















Primary pathogen (only pathogen or
pathogen with the highest bacterial load)
Haemophilus inﬂuenzae 80 (52)
Streptococcus pneumoniae 30 (19)
Moraxella catarrhalis 30 (19)
Pseudomonas spp. 6 (4)
Haemophilus parainﬂuenzae 5 (3)
Staphylococcus aureus 1 (0.6)
Escherichia coli 1 (0.6)
Chlamydophila pneumoniae 1 (0.6)
Mycoplasma pneumoniae 1 (0.6)
aA sample with >25 polymorphonuclear leukocytes and <10 squamous epithelial
cells per low-power ﬁeld in a Gram-stained sputum was deﬁned as a represen-
tative sputum sample.
TABLE 3. Test characteristics of sputum colour reported by
patients and assessed sputum colour (colour chart [4]) as




with a colour chart
Sensitivity (%) 73 90
Speciﬁcity (%) 39 52
PPV (%) 65 82
NPV (%) 49 68




PPV, positive predictive value; NPV, negative predictive value.
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CRP levels between patients with reported purulent sputum
and mucoid sputum (28 mg/L (IQR 8–88) and 29 mg/L
(IQR 7–76), respectively, p 0.36). By contrast, assessed
sputum purulence was associated with signiﬁcantly higher
CRP levels than assessed mucoid sputum (36 mg/L (IQR 12–
92) and 9 mg/L (IQR 4–39), respectively, p <0.001) (Fig. 2).
Discussion
This study demonstrates that sputum colour assessed with a
sputum colour chart is a better marker for bacterial involve-
ment than sputum colour reported by patients. Assessed
sputum colour is also clearly related to sputum bacterial load
and, in particular, systemic inﬂammation consistent with
infection, whereas reported sputum colour is not.
Two other studies speciﬁcally investigated the diagnostic
accuracy of routinely assessed sputum colour [4,5]. Stockley
et al. [4] studied 121 patients with AECOPD, and assessed
sputum colour with a nine-point colour chart. Patients with
purulent sputum were treated with antibiotics, and those
with mucoid sputum were not. All patients with mucoid spu-
tum recovered without antibiotic therapy. The sputum col-
our chart had a sensitivity of 85% and a speciﬁcity of 84%. It
was pointed out that 40% of the patients with mucoid spu-
tum subjectively reported a change in sputum colour. The
authors concluded that assessment of sputum colour can be
(a)
(b)
FIG. 1. Mean log bacterial load (± standard error of the mean and
p-value) of the primary pathogen for mucoid and purulent sputum as




FIG. 2. Mean serum C-reactive protein (± standard error of the mean
and p-value) in exacerbations with mucoid and purulent sputum as
reported by patients (a) and as assessed with a sputum colour chart
(b) [4].
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used to avoid unnecessary antibiotic therapy in patients with
mucoid sputum. In our study, the speciﬁcity of assessed spu-
tum colour was only 52%. The fact that our population con-
sisted of hospitalized patients with more severe COPD
might explain this difference. More severe non-bacterial
exacerbations could result in intense neutrophilic airway
inﬂammation and increased myeloperoxidase levels, with sub-
sequent sputum discolouration; that is, severe airway inﬂam-
mation in the absence of bacterial infection might result in
false-positive sputum purulence. Also, antibiotic therapy
could result in a false-negative sputum culture with sputum
purulence, although our protocol ensured that sputum sam-
ples were collected before the start of antimicrobial therapy,
making this unlikely. Finally, Stockley et al. [4] used a nine-
point sputum colour chart, whereas we used a commercially
available ﬁve-point sputum chart, which is based on the nine-
point chart.
Allegra et al. [5] investigated a ten-point colorimetric
scale for assessment of sputum colour. White or grey spu-
tum samples were considered to be mucoid, and yellow,
green and brown sputum samples were considered to be
purulent. Although a higher rate of bacterial growth was
found in purulent samples, 78% of mucoid samples showed
bacterial growth. Deepening sputum colour (from yellowish
to brownish) was associated with Gram-negative bacteria,
particularly Pseudomonas aeruginosa and Enterobacteriaceae.
Interestingly, patient and investigator deﬁnitions of
sputum colour were conﬁrmed in only 41% and 45%,
respectively, of cases after assessment with the colorimetric
scale.
Bearing these two studies in mind, one would expect that
sputum colour reported by patients would not be a valuable
marker for bacterial infection, which is conﬁrmed by the cur-
rent study. There could be several explanations. First, not all
patients routinely inspect their expectorated sputum, and
the answer given to the doctor could be a ‘best guess’. Sec-
ond, sputum colour can change rapidly, especially during
acute exacerbations. A patient who reports mucoid sputum
could expectorate a purulent sample for culture, and
vice versa. Finally, expectorated sputum is not always
homogeneous. A predominantly mucoid sample can contain
purulent parts, which can be confusing. In contrast with our
study, Soler et al. [9] concluded that self-reported sputum
purulence is a good predictor of bacterial infection and that
self-reported mucoid sputum precludes it (negative
predictive value of 94%). We found bacteria in 51% of sam-
ples reported as mucoid and 32% of samples assessed as
mucoid, and other studies have reported even higher rates
of bacterial infection in samples assessed as mucoid [4,5].
This difference might be explained by the fact that 81% of
our reported mucoid sputum samples were representative,
as opposed to 6% in the study of Soler et al., and by the
fact that they used protective brush specimens (PSBs) for
culturing.
An important problem for clinicians is whether the pres-
ence of bacteria in a sputum sample represents infection or
colonization. In approximately 50% of exacerbations, signiﬁ-
cant amounts of potential bacterial pathogens can be isolated
from PSBs obtained by bronchoscopy [9–11]. However, the
same pathogens are found in the airways of patients in a sta-
ble phase of the disease [11–15]. Isolation of a new bacterial
strain is more likely to represent infection, but this cannot
be readily assessed in daily practice [16]. Another possible
way in which to discern infection from colonization is assess-
ment of the bacterial load. A study using PSB specimens
found that patients with exacerbations had higher airway
bacterial loads than patients in a stable phase [11]. Further-
more, an increase in airway bacterial load has been associ-
ated with increased airway inﬂammation [17,18]. These and
other observations led to the ‘rise and fall’ or quantitative
hypothesis, i.e. that exacerbations are caused by a local
inﬂammatory response to a rise of the bacterial load above a
certain threshold [19]. Finally, one could assess local and sys-
temic inﬂammation in order to distinguish infection from col-
onization. Neutrophilic airway inﬂammation and systemic
inﬂammation are more intense with well-deﬁned bacterial
exacerbations than with non-bacterial exacerbations [20].
Stockley et al. found that sputum colour is correlated with
airway inﬂammation [21] and systemic inﬂammation [4]. The
current study conﬁrms the relationship between assessed
sputum colour and systemic inﬂammation (serum CRP). The
fact that assessed sputum colour is related to bacterial load
and to systemic inﬂammation strengthens its value as a mar-
ker in AECOPDs.
In conclusion, sputum colour reported by patients is not
useful in determining bacterial presence in AECOPDs.
Although its speciﬁcity is limited, assessed sputum colour is
clearly superior in predicting bacterial presence and is also
related to bacterial load and systemic inﬂammation, and
might thereby help clinicians to distinguish infection from col-
onization. We therefore advise inspection of expectorated
sputum with a validated sputum colour chart in patients with
AECOPDs.
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